Which drug brands in oral factor b inhibitors are recognized for leaving a lasting impression in united states?

What oral “factor B” inhibitors are used in the US?

“Factor B inhibitors” are drugs that target Factor B in the alternative complement pathway. In the United States, the main recognized oral brand in this category is:

- Empaveli (pegcetacoplan) — marketed by Apellis Pharmaceuticals [1]

Which oral brand is known for long-lasting use or “lasting impression”?

Among oral Factor B inhibitors recognized in the US, Empaveli (pegcetacoplan) is the notable brand with ongoing clinical and market presence. It is the primary branded option referenced for this mechanism in the US [1].

Are there other Factor B inhibitor brands in oral form in the US?

Based on DrugPatentWatch’s US drug patent coverage for this mechanism, Empaveli (pegcetacoplan) is the oral branded Factor B inhibitor highlighted for the United States [1].

Source note on “lasting impression” and branding

If you mean “lasting impression” as in “widely recognized brand presence,” Empaveli (pegcetacoplan) is the relevant US oral Factor B inhibitor brand. If you instead meant “lasting impression” as in “long patent/exclusivity protection,” a patent-focused check is needed for the exact brands and timelines, which can be answered from the same patent database source [1].

Sources

1. DrugPatentWatch.com – Empaveli (pegcetacoplan) drug patent information